Skip to Content

Clolar Approval History

  • FDA approved: Yes (First approved December 28th, 2004)
  • Brand name: Clolar
  • Generic name: clofarabine
  • Dosage form: for Intravenous Infusion
  • Company: Genzyme Corp.
  • Treatment for: Acute Lymphoblastic Leukemia

Clolar (clofarabine) is a purine nucleoside anti-metabolite indicated for the treatment of children with refractory or relapsed acute lymphoblastic leukemia (ALL).

Development History and FDA Approval Process for Clolar

Dec 28, 2004Approval Clolar Genzyme Corp. - Treatment for Leukemia in Children
Dec  1, 2004FDA Advisory Committee Recommends Accelerated Clofarabine Approval for Most Common Pediatric Leukemia; FDA to Make Approval Decision by End of Year
Sep 28, 2004ILEX's Clofarabine Scheduled For FDA Advisory Committee Review; ODAC to Review Pivotal Data for Pediatric Acute Leukemia
Aug 24, 2004ILEX Updates Clofarabine NDA with Encouraging Results; Additional Patient Data Resets FDA Action Date
Jul 21, 2004FDA Will Grant ILEX's Clofarabine Additional Six-Month Pediatric Exclusivity; Incentive Provides Extended Patent Protection Upon Marketing Approval
Jun  3, 2004FDA Begins Priority Review of ILEX NDA for Clofarabine in Pediatric Acute Leukemia; Filing Acceptance Indicates Start of Official Review Period
Mar 31, 2004ILEX Completes New Drug Application for Clofarabine; Filing Offers Hope to Children with Most Difficult-to-Treat Leukemias

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.